Patent intelligence · US
US 11357842
PD-L1 targeting DNA vaccine for cancer immunotherapy
PD-L1 targeting DNA vaccine for cancer immunotherapy
Patent details — US 11357842
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 14, 2022
- Expiration
- Jun 9, 2042
- Applicant
- Vaximm AG
- Claims
- 14
- CPC classes
- A61K, A61K2039/522, A61K2039/523, A61K39/0011
Quick answer
US 11357842 (PD-L1 targeting DNA vaccine for cancer immunotherapy) is held by Vaximm AG. Status: granted. Granted Jun 14, 2022. Expires Jun 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vaximm AG
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K2039/522, A61K2039/523, A61K39/0011, A61K39/001104, A61K39/001111
More from Vaximm AG
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Frequently asked questions
What is US patent 11357842?
US 11357842 (PD-L1 targeting DNA vaccine for cancer immunotherapy) is held by Vaximm AG. Status: granted. Granted Jun 14, 2022. Expires Jun 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11357842?
Vaximm AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 11357842 expire?
Our index shows an expiration date of Jun 9, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.